Eco Material Technologies is the largest marketer and distributor of fly ash and the leading producer of sustainable cementitious products in the United States. We are the first national, environmentally focused, near-zero carbon cement producer in the country. Combining the Boral Resources business with Green Cement Inc., Eco Material is the leading marketer and distributor of fly ash, with 50% volume share in the US and the industry's only true national footprint of logistics networks and distribution channels. We also maintain patented technology that can utilize fly ash and other supplementary materials to produce innovative, low carbon products as green substitutes for Portland cement. We can also beneficially use fly ash that is unmarketable today by transforming it with our technology into a high value manufactured product with environmental benefits. The company was founded in early 2022 and is now backed by three very strong sponsors including Warburg Pincus (New York) and One Equity Partners (Chicago). Reporting to the Chairman and CEO, the CFO will be responsible for leading all aspects of the company's financial function, including accounting, control, treasury, capital budgeting and forecasting, financial reporting, metrics and tax planning. The CFO will also be responsible for all IT activities incl. N&I as well as Helpdesk and Software Development. The CFO will proactively partner with the CEO and peer management team members to increase shareholder value through the attainment of operational and financial goals. Additionally, the CFO will optimize corporate earnings power and cash flow by helping the business identify and capture revenue and margin growth, cost reduction and operational efficiency opportunities, incl. working capital management. Ultimately the CFO will prepare and lead the sale of the business along with the CEO and the Sponsor group.

Tensar International is a world leader and expert in technology driven solutions for soil reinforcement and ground stabilization. Tensar's products offer a unique value proposition to customers by significantly reducing overall construction costs, shortening required construction times, and increasing the useful life of the resulting infrastructure. The company has a global footprint with sales in approx. 80 countries. Headquartered near Atlanta, Georgia, Tensar has manufacturing facilities in Morrow, Georgia; Shadsworth, England; Wuhan, China; and St. Petersburg, Russia. Castle Harlan, Inc., the New York private equity investment firm has closed on the acquisition of Tensar Corporation in July 2014 for a total purchase price of $400 Million. Founded in 1987, Castle Harlan Inc. is a global private-equity firm focused on making control investments in middle-market companies. As Chief Financial Officer I will ensure the Company's financial strength and enable its profitable operation by planning, directing, and leading the financial activities of the organization globally to include financial planning and analysis, treasury, budgeting, audit, tax, accounting and FX/currency transactions. I will also lead the Information Technology and Risk Management functions. As a key member of the Executive Leadership Team and reporting to the Board and the CEO, I will be responsible with my colleagues to further the objectives of the Company including a culture tied to delivering peer-beating results for its shareholders. Specific responsibilities will include the development and prioritization of capitalization strategies and managing the overall balance sheet as well as leading the interaction with external relationships (investors, lenders, bankers, auditors, etc.). Finally, I supported the preparation of the offering memorandum and prospectus, as part of a liquidity event that was successfully executed in 2022. Tensar was sold to Commercial Metals (NYSE: CMC).

Contract Laboratory d.b.a. UTC Lab/Renaissance RX is a leading personalized medicine company with a mission to improve the way physicians manage medications and track drug adherence. The Company's products and services are designed to produce better data and healthier patients. Renaissance RX provides a host of advanced lab services including pharmacogenomics, toxicology testing, and pharmaceutical compounding solutions. To complement lab services and help ensure drug adherence, Ren RX offers access to its unique online medication portal, the Virtual PharmD Intelligence Engine, as well as pain relief ointments compounded to meet each patient's specific needs. Founded in 2012, the company is located in New Orleans and serves physicians and patients in more than 30 states.As Chief Financial Officer I serve as a key advisor to the CEO and the Board of Directors. My priorities will be to secure appropriate capital to support product rollout and the company's strong growth as well as manage and report operational results while seeking to maintain/expand positive EBITDA and Cash Flow.

Remedi SeniorCare®, an innovative long-term care pharmacy provider, is one of the nation’s largest institutional pharmacy companies. Through the development and deployment of innovative technologies and web-based solutions, Remedi enables long-term care facility operators and providers to efficiently deliver optimal medication management and unequalled resident safety and accuracy while also significantly reducing drug costs. The company closed a $300 million equity commitment from affiliates of New York-based Centerbridge Partners, L.P. which will support the continued growth of Remedi’s customer-driven innovations, as well as acquisitions and greenfield start-up pharmacies in new markets across the U.S. This investment gives Remedi the strength to transform the way long-term care facilities manage medication administration for their residents. Remedi’s founding investor, Sterling Partners, will continue to participate in the company’s ongoing growth. As CFO I provide strategic financial and organizational leadership and direction to the CEO and Board of Directors in order to successfully execute Remedi’s growth strategy. I lead Remedi’s finance, accounting, treasury, tax and procurement team, and set the overall strategy for these groups and be responsible for transforming the areas toward becoming true business partners with the rest of the organization.

Aptuit is a Pharmaceutical Services company that conducts research, development and manufacturing on a contract basis for both large and small innovators. Today, Aptuit serves more than 800 customers and employs over 2,700 in 18 global facilities. As EVP and Chief Financial Officer I assume full responsibility for the global Finance function as well as global IT and Procurement. More specifically major responsibilities include:- Set direction, plans and objectives of the global Finance team with the requirements of the business- Focus on improving the core finance operations incl. reporting, order-to-cash, procurement, capital management, SOX 404 compliance- As a member of the Executive Committee, be an active participant in reshaping and implementing the new strategy of the Company- Lead discussions on Company's financial performance with external constituencies in particular private-equity partners, bankers and external auditors- Prepare the company for a liquidity event

A global leader in hospitality industry with $16 bil revenue, of which 45% generated in North America. Major markets include Healthcare, Higher Education, Defense and Corporate Services. Total employees of 135,000 in North America. Responsible for strategic direction and leadership for financial activities. Total staff includes 9 direct and 420 total. - Provided internal and external constituencies with relevant, high integrity, transparent financial information and analyses- Reduced closing time by producing consolidated financials in 8 days, from 15- Aligned US GAAP with IFRS in less than a year- Led compliance to SOX 404 compliance, resulting in one of the first European companies to be Sarbanes compliant in FY 2006- Effectively developed new tax strategies which resulted in multi-year cash savings- Recovered $10M+ of insurance payment following business interruption losses- Led employee diversity and inclusion effort as executive sponsor of Pan Asian Network group.

Aventis Pharmaceuticals (now part of sanofi-aventis) is a global Life Sciences organization having primary activities in the Pharmaceutical, Human vaccines and Crop Protection arena. Company is headquartered in Strasbourg, France and was created from the merger of Hoechst AG (Germany) and Rhone-Poulenc SA (France). - Vice President, Controller, R&D, Bridgewater, NJ. Responsible for $4 bil+ of global R&D budget for all research centers in the world. Directed capital allocation, biotech screening and acquisitions, competitive intelligence and strategic planning. - Vice President, CFO, Aventis Crop Science, Lyon, France.Reporting to Corporate CEO, revenue scope of $7.0 bil operating in 50 countries and all crop protection market segments.- Vice President, CFO Aventis Crop Science US, RTP, NC. Appointed CFO for newly merged company in North America and achieved successfully 20%+ synergies in first 18 months following merger.

Rhone-Poulenc SA was a diversified international group operating in the Chemicals, Specialty Chemicals, Ag Chem and Pharmaceutical industry. RPSA had revenue in the range of $10 bil+ in this period growing by more than 60% over a 10 year period. - Rhone Poulenc Agro, Lyon, France, Corporate Controller. A $2.2 billion Division operating in 50 countries. Successfully deployed EVA as a new global management concept for progress and incentive measurement. Achieved substantial cash flow and profitability improvement leading to division becoming self funding.- Clause Harris Moran Seeds, Paris, France, CFO. A joint venture between Rhone-Poulenc and Lafarge Coppee in the vegetable and flower seeds business generating $350 mil+ in sales.- Rhone Poulenc Animal Nutrition, Atlanta, Georgia, US Controller- Rhone Poulenc SA, Paris, France, Senior Auditor, Group Internal Audit & Procedures Dept.